Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

RCT (n=130) found nab-paclitaxel+gemcitabine is similarly active (surgical conversion rate 35·9% vs. 43·9%; OR 0·72; 95% CI 0·35–1·45;p=0·38) and safe as nab-paclitaxel plus gemcitabine followed by FOLFIRINOX as multidrug induction chemotherapy regimens in this population.

Lancet Gastroenterology and Hepatology